Arkos Global Advisors’s Idexx Laboratories IDXX Stock Holding History

Arkos Global Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-541	Closed	-$346K	–	145
2025 Q3	$346K	Buy	+541	New	+$328K	0.04%	115

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Arkos Global Advisors's IDXX Position: Q4 2025 in Review

Arkos Global Advisors sold out of Idexx Laboratories (IDXX) in Q4 2025, closing a stake of 541 shares — an estimated $346K sold.

Arkos Global Advisors first reported a position in IDXX in Q3 2025 and held it in 1 quarter. The position peaked at $346K in Q3 2025. 1,386 funds tracked by Wall St. Rank hold IDXX as of Q4 2025.

Arkos Global Advisors reported no remaining Idexx Laboratories position as of Q4 2025 after selling out during the quarter.
Arkos Global Advisors sold 541 Idexx Laboratories shares in Q4 2025, an estimated $346K.
Arkos Global Advisors first reported a position in Idexx Laboratories in Q3 2025 and held it in 1 quarter.
Arkos Global Advisors's Idexx Laboratories position peaked at $346K in Q3 2025.
1,386 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2025.

Based on Arkos Global Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.